Myriad Genetics (MYGN) Confirms BRACAnalysis CDx Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study
Tweet Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that its BRACAnalysis CDx® companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE